We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Genomatica Stock

Invest in or calculate the value of your shares in Genomatica or other pre-IPO companies through EquityZen's platform.

Get Started

Genomatica Stock (GENO)

Genomatica manufactures sustainable chemicals from renewable feedstocks.

About Genomatica Stock

Founded

2000

Headquarters

San Diego, CA, US

Industries

Software, Artificial Intelligence, Financial Services

Genomatica is a widely-recognized leader in bioengineering and aims to lead a transition to more sustainable materials. It develops bio-based process technologies that enable a better way to produce widely-used chemicals, from alternative feedstocks, with better economics, sustainability and performance. Genomatica has earned widespread acclaim for its technology; has commercialized processes for the chemical butanediol (for biodegradable plastics and apparel) and for butylene glycol (cosmetics and personal care); and is working on bio-nylon. Awards include the Kirkpatrick Award, for “the most noteworthy chemical engineering technology commercialized in the world” and the ICIS Innovation Award for its Brontide(TM) butylene glycol.

Genomatica Management

Leadership team at Genomatica

Co-Founder, President & CEO

Christophe Schilling

Executive Vice President, Process Technology

Jeff Lievense

Locked Features

Join now and verify your accreditation status to gain access to:

  • Genomatica Current Valuation
  • Genomatica Stock Price
  • Genomatica Management
  • Available deals in Genomatica and all other companies with relevant Deal Offering documents
  • EquityZen's proprietary data and insights, which may include
    • Genomatica Cap Table and Funding History by Share Class and Liquidity Preferences
    • Genomatica Revenue and Financials
    • Genomatica Highlights
    • Genomatica Business Model
    • Genomatica Risk Factors
  • Genomatica Research Report from SACRA Research
Join Now

Trading Genomatica Stock

How to invest in Genomatica stock?

Accredited investors can buy pre-IPO stock in companies like Genomatica through EquityZen funds. These investments are made available by existing Genomatica shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Genomatica stock?

Shareholders can sell their Genomatica stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."